Breaking News2 years ago
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
[ad_1] ABSTRACT: 4008 Newswise — CHICAGO ― HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The...